---
import BaseLayout from '../layouts/BaseLayout.astro';
---

<BaseLayout title="The Science - Sarcoma Research">
  <div class="relative min-h-screen px-6 pt-8 pb-12 md:pt-12 md:pb-16">
    <div class="max-w-4xl mx-auto z-10">
      <!-- Header -->
      <div class="mb-12 md:mb-16">
        <h1 class="text-4xl md:text-5xl font-bold mb-4 text-purple-700 text-center">
          The Science Behind ASPSCR1-TFE3 Sarcoma
        </h1>
        <p class="text-lg text-gray-700 text-center">
          Understanding the molecular mechanisms driving alveolar soft part sarcoma
        </p>
      </div>

      <!-- The Mechanism Section -->
      <section class="mb-12 md:mb-16">
        <div class="bg-white/80 backdrop-blur-sm rounded-lg p-8 border border-purple-100 shadow-sm">
          <h2 class="text-2xl md:text-3xl font-bold mb-4 text-purple-700">
            The Mechanism: The Translocation t(X;17)(p11;q25)
          </h2>
          
          <div class="space-y-6">
            <p class="text-lg text-gray-700 leading-relaxed">
              At the heart of alveolar soft part sarcoma (ASPS) lies a precise chromosomal rearrangement: <span class="font-semibold">t(X;17)(p11;q25)</span>. This translocation breaks two chromosomes—the X chromosome and chromosome 17—at specific locations and exchanges their genetic material.
            </p>

            <div class="bg-purple-800/30 border border-purple-600/50 rounded-lg p-6">
              <h3 class="text-lg font-semibold text-purple-700 mb-3">The Molecular Event</h3>
              <ul class="space-y-3 text-gray-700">
                <li class="flex items-start gap-3">
                  <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                  <span>The <span class="font-semibold">ASPSCR1 gene</span> (located on chromosome 17) breaks at position q25</span>
                </li>
                <li class="flex items-start gap-3">
                  <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                  <span>The <span class="font-semibold">TFE3 gene</span> (located on the X chromosome) breaks at position p11</span>
                </li>
                <li class="flex items-start gap-3">
                  <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                  <span>These fragments recombine, creating a <span class="font-semibold">fusion protein: ASPSCR1-TFE3</span></span>
                </li>
              </ul>
            </div>

            <p class="text-lg text-gray-700 leading-relaxed">
              This balanced translocation is found in virtually 100% of ASPS cases, making it a pathognomonic hallmark of the disease. The breakpoint occurs in-frame, meaning the fusion gene produces a functional, aberrant protein rather than a non-functional truncation.
            </p>
          </div>
        </div>
      </section>

      <!-- The Target Section -->
      <section class="mb-12 md:mb-16">
        <div class="bg-white/80 backdrop-blur-sm rounded-lg p-8 border border-purple-100 shadow-sm">
          <h2 class="text-2xl md:text-3xl font-bold mb-4 text-purple-700">
            The Target: ASPSCR1-TFE3 Fusion Protein
          </h2>

          <div class="space-y-6">
            <p class="text-lg text-gray-700 leading-relaxed">
              The ASPSCR1-TFE3 fusion protein is a <span class="font-semibold">constitutively active transcription factor</span>—a master regulator of gene expression gone awry.
            </p>

            <div class="grid md:grid-cols-2 gap-6">
              <div class="bg-purple-800/30 border border-purple-600/50 rounded-lg p-6">
                <h3 class="text-lg font-semibold text-purple-700 mb-3">Why It's a Transcription Factor</h3>
                <ul class="space-y-2 text-gray-700 text-sm">
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span>TFE3 contributes its <span class="font-semibold">DNA-binding domain</span>, allowing it to attach to specific DNA sequences</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span>ASPSCR1 contributes <span class="font-semibold">activation domains</span> that turn on target genes</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span>The result: a fusion protein that is <span class="font-semibold">always "on"</span>, constantly activating genes</span>
                  </li>
                </ul>
              </div>

              <div class="bg-purple-800/30 border border-purple-600/50 rounded-lg p-6">
                <h3 class="text-lg font-semibold text-purple-700 mb-3">Driving Angiogenesis</h3>
                <ul class="space-y-2 text-gray-700 text-sm">
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span>ASPSCR1-TFE3 activates <span class="font-semibold">angiogenic pathways</span></span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span>It upregulates <span class="font-semibold">VEGF</span> (vascular endothelial growth factor) and related signaling molecules</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span>It promotes <span class="font-semibold">lysosomal biogenesis</span> and metabolic reprogramming</span>
                  </li>
                </ul>
              </div>
            </div>

            <p class="text-lg text-gray-700 leading-relaxed">
              Unlike normal TFE3, which is tightly regulated and inactive most of the time, the ASPSCR1-TFE3 fusion bypasses all regulatory checkpoints. This unrelenting activation of angiogenic programs makes tumor cells hyperdependent on new blood vessel formation—a vulnerability that offers potential therapeutic opportunities.
            </p>
          </div>
        </div>
      </section>

      <!-- Why It's Unique Section -->
      <section>
        <div class="bg-white/80 backdrop-blur-sm rounded-lg p-8 border border-purple-100 shadow-sm">
          <h2 class="text-2xl md:text-3xl font-bold mb-4 text-purple-700">
            Why It's Unique: Resistance & Vascularization Dependence
          </h2>

          <div class="space-y-6">
            <p class="text-lg text-gray-700 leading-relaxed">
              ASPSCR1-TFE3 sarcoma represents a distinct and challenging entity due to two interconnected properties:
            </p>

            <div class="space-y-4">
              <div class="bg-purple-800/30 border border-purple-600/50 rounded-lg p-6">
                <h3 class="text-lg font-semibold text-purple-700 mb-3">1. Intrinsic Chemotherapy Resistance</h3>
                <p class="text-gray-700 leading-relaxed">
                  Traditional chemotherapy agents work by inducing DNA damage or disrupting microtubules. ASPSCR1-TFE3 sarcoma cells are remarkably resistant to these approaches because:
                </p>
                <ul class="space-y-2 mt-3 text-gray-700 text-sm">
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span><span class="font-semibold">Enhanced DNA repair</span>: The fusion protein upregulates genes involved in repairing chemotherapy-induced DNA damage</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span><span class="font-semibold">Altered metabolism</span>: Tumor cells reprogram their metabolism, reducing their dependence on proliferation signals targeted by conventional drugs</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span><span class="font-semibold">Survival pathway activation</span>: The fusion drives anti-apoptotic (anti-cell-death) pathways, protecting tumor cells from drug-induced damage</span>
                  </li>
                </ul>
              </div>

              <div class="bg-purple-800/30 border border-purple-600/50 rounded-lg p-6">
                <h3 class="text-lg font-semibold text-purple-700 mb-3">2. Extreme Angiogenesis Dependence</h3>
                <p class="text-gray-700 leading-relaxed">
                  ASPSCR1-TFE3 drives one of the most vascularized soft tissue sarcomas known. This has profound implications:
                </p>
                <ul class="space-y-2 mt-3 text-gray-700 text-sm">
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span><span class="font-semibold">Tumor growth bottleneck</span>: The tumor cannot grow beyond a few millimeters without new blood vessels. This creates a therapeutic vulnerability—anti-angiogenic agents may have outsized effects</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span><span class="font-semibold">Metabolic stress</span>: Blocking angiogenesis cuts off oxygen and nutrient supply, triggering metabolic crisis in a tumor that has become dependent on high blood flow</span>
                  </li>
                  <li class="flex items-start gap-2">
                    <span class="text-purple-400 font-bold flex-shrink-0">•</span>
                    <span><span class="font-semibold">Therapeutic opportunity</span>: Targeting VEGF, TFE3 activity, or downstream metabolic pathways may be far more effective than traditional chemotherapy</span>
                  </li>
                </ul>
              </div>
            </div>

            <div class="bg-purple-700/20 border border-purple-600/50 rounded-lg p-6 mt-6">
              <p class="text-gray-700 leading-relaxed">
                In summary, ASPSCR1-TFE3 sarcoma's resistance to conventional therapy and its extreme dependence on angiogenesis define it as a unique disease. This biology opens new therapeutic avenues: instead of trying to poison the tumor with drugs it can resist, we can starve it by cutting off its blood supply, or directly inhibit the fusion protein itself.
              </p>
            </div>
          </div>
        </div>
      </section>

      <!-- Call to Action -->
      <div class="mt-12 md:mt-16 text-center">
        <p class="text-lg text-gray-700 mb-6">
          Interested in our research approach?
        </p>
        <a href="/research" class="inline-block bg-purple-600 hover:bg-purple-500 text-white font-semibold px-8 py-3 rounded-full transition-colors">
          Explore Our Research & Data
        </a>
      </div>
    </div>
  </div>

  <script type="application/ld+json">
  {
    "page": "The Science",
    "disease": "Alveolar Soft Part Sarcoma",
    "driver": "ASPSCR1–TFE3 fusion",
    "mechanisms": ["angiogenesis dependency", "TFE3-driven transcription"],
    "therapeutic_vulnerabilities": ["VEGF pathway", "MET signaling"],
    "current_therapies": ["atezolizumab", "pazopanib"],
    "research_focus": ["target discovery", "computational modeling"]
  }
  </script>
</BaseLayout>

<script type="application/ld+json">
{
  "page": "The Science",
  "disease": "Alveolar Soft Part Sarcoma",
  "driver": "ASPSCR1–TFE3 fusion",
  "mechanisms": ["angiogenesis dependency", "TFE3-driven transcription"],
  "therapeutic_vulnerabilities": ["VEGF pathway", "MET signaling"],
  "current_therapies": ["atezolizumab", "pazopanib"],
  "research_focus": ["target discovery", "computational modeling"]
}
</script>
